Edna Mozes Professor Edna Mozes
Professor of Immunology
E-mail: edna.mozes@weizmann.ac.il
Phone: +972-8-934-3646
Fax: +972-8-934-4173
Location: Wolfson Bldg., Room 526

 Publications (last 3 years)

  1. D. Luger, M. Dayan, H. Zinger, J.-P. Liu and E. Mozes. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J. Clin. Immunol. 24: 579-590 (2004).

  2. N. Mauermann, Z. Sthoeger, H. Zinger and E. Mozes. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin. Exp. Immunol. 137: 513-520 (2004).

  3. M. Dayan, Z. Sthoeger, A. Neiman, J. Abarbanel, M. Sela and E. Mozes. Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis. Human Immunol. 65: 571-577 (2004).

  4. M. Sela and E. Mozes. Therapeutic vaccines in autoimmunity. Proc. Natl. Acad. Sci. USA 101: 14586-14592 (2004).

  5. U. Sela, R. Hershkoviz, L. Cahalon, O. Lider and E. Mozes. Down-regulation of stromal cell-derived factor-1a-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF- secretion. J. Immunol. 174: 302-309 (2005).

  6. U. Sela, N. Mauermann, R. Hershkoviz, H. Zinger, M. Dayan, L. Cahalon, J.-P. Liu, E. Mozes and O. Lider. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF- mediated suppression of LFA-1 and CD44 expression and function. J. Immunol. 175:7255-7263 (2005).

  7. E. S. Husebye, Z.M. Sthoeger, M. Dayan, H. Zinger, D. Elbirt, M. Levite and E. Mozes. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 64: 1210-1213 (2005).

  8. E. Mozes, J. Lovchik, H. Zinger and D.S. Singer. MHC class I expression regulates susceptibility to spontaneous autoimmune disease in (NZBxNZW)F1 mice. Lupus 14: 308-314 (2005).

  9. M.J. Rapoport, A. Sharabi, D. Aharoni, O. Bloch, H. Zinger, M. Dayan and E. Mozes. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin. Immunol. 117: 262-270 (2005).

  10. H. Ben-David, M. Sela and E. Mozes. Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+ CD25+ -regulated events leading to apoptosis. Proc. Natl. Acad. Sci. USA 102: 2028-2033 (2005).

  11. B.V. Aruna, M. Sela and E. Mozes. Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cells. Proc. Natl. Acad. Sci. USA 102: 10285-10290 (2005).

  12. B.V. Aruna, H. Ben-David, M. Sela and E. Mozes. A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis. Immunology 118:413-424 (2006).

  13. B.V. Aruna, M. Sela and E. Mozes. Down regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+CD25+ regulatory cells. J. Neuroimmunol. 177: 63-75 (2006).

  14. A. Sharabi, A. Haviv, H. Zinger, M. Dayan and E. Mozes. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: Different effects on cytokines and apoptosis. Clin. Immunol. 119:146-155 (2006).

  15. E. Voronov, M. Dayan, H. Zinger, L. Gayvoronsky, J.-P. Liu, Y. Iwakura, R.N. Apte and E. Mozes. IL-1-deficient mice are resistant to induction of experimental SLE. Eur. Cytokine Netw. 17: 109-116 (2006).

  16. E.S. Husebye, E. Bratland, G. Bredholt, M. Fridkin, M. Dayan and E. Mozes. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope. Endocrinology 147: 2411-2416 (2006).

  17. H. Ben-David, B.V. Aruna, R. Seger, M. Sela and E. Mozes. A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses. Proc. Natl. Acad. Sci. USA 103:18232-18237 (2006).

  18. Z. Sthoeger, A. Neiman, D. Elbirt, H. Zinger, E. Magen, R. Burstein, S. Eitan, J. Abarbanel and E. Mozes. High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: A clinical and serologic study. Am. J. Med. Sci. 331:4-9 (2006).

  19. U. Sela, M. Dayan, R. Hershkoviz, L. Cahalon, O. Lider and E. Mozes. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur. J. Immunol. 36: 2971-2980 (2006).

  20. A. Sharabi, H. Zinger, M. Zborowsky, Z.M. Sthoeger and E. Mozes. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-. Proc. Natl. Acad. Sci. USA 103: 8810-8815 (2006).

  21. H. Ben-David, B.V. Aruna, M. Sela and E. Mozes. A dual altered peptide ligand inhibits myasthenia gravis associated responses by inducing phosphorylated extracellular-regulated kinase 1,2 that upregulates CD4+CD25+Foxp3+ cells. Scandinavian J. Immunol. 65:567-576 (2007).

  22. A. Elmann, A. Sharabi, M. Dayan, H. Zinger, R. Ophir and E. Mozes. Altered gene expression in mice with lupus treated with Edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum. 56: 2371-2381 (2007).

  23. A. Sharabi, H. Azulai, Z.M. Sthoeger and E. Mozes. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophophamide: similarities and differences in the mechanisms of action. Immunology 121: 248-257 (2007).

  24. A. Sharabi, D. Luger, H. Ben-David, M. Dayan, H. Zinger and E. Mozes. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J. Immunol. 179: 4979-4987 (2007).

  25. H. Ben-David, A. Sharabi, M. Dayan, M. Sela and E. Mozes. The role of CD8+CD28- regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand. Proc. Natl. Acad. Sci. 104: 17459-17464 (2007).